Cargando…

An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy

BACKGROUND AND AIM: The exact COVID-19 severity is still not well defined and it is hotly debated due to a few methodological issues such as the uncertainties about the spread of the SARS-CoV-2 infection. METHODS: We investigated COVID-19 case-fatality rate and infection-fatality rate in 2020 in Ita...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippini, Tommaso, Zagnoli, Federico, Bosi, Matteo, Giannone, Maria Edvige, Marchesi, Cristina, Vinceti, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851028/
https://www.ncbi.nlm.nih.gov/pubmed/34739462
http://dx.doi.org/10.23750/abm.v92iS6.12241
_version_ 1784652742028951552
author Filippini, Tommaso
Zagnoli, Federico
Bosi, Matteo
Giannone, Maria Edvige
Marchesi, Cristina
Vinceti, Marco
author_facet Filippini, Tommaso
Zagnoli, Federico
Bosi, Matteo
Giannone, Maria Edvige
Marchesi, Cristina
Vinceti, Marco
author_sort Filippini, Tommaso
collection PubMed
description BACKGROUND AND AIM: The exact COVID-19 severity is still not well defined and it is hotly debated due to a few methodological issues such as the uncertainties about the spread of the SARS-CoV-2 infection. METHODS: We investigated COVID-19 case-fatality rate and infection-fatality rate in 2020 in Italy, a country severely affected by the pandemic, basing our assessment on publicly available data, and calculating such measures during the first and second waves. RESULTS: We found that province-specific crude case-fatality rate in the first wave (February-July 2020) had a median value of 12.0%. Data about infection-fatality rate was more difficult to compute, due to large underestimation of SARS-CoV-2 infection during the first wave when asymptomatic individuals were very rarely tested. However, when using reference population-based seroprevalence data for anti-SARS-CoV-2 antibodies collected in May-July 2020, we computed an infection-fatality rate of 2.2%. During the second wave (Sep-Dec 2020), when SARS-CoV-2 testing was greatly increased and extended to many asymptomatic individuals, we could only compute a ‘hybrid’ case/infection-fatality rate with a value of 2.2%, similar to the infection-fatality rate of the first wave. CONCLUSIONS: Overall, this study allowed to assess the COVID-19 case- and infection-fatality rates in Italy before of variant spread and vaccine availability, confirming their high values compared with other airborne infections like influenza. Our findings for Italy were similar to those characterizing other Western European countries.
format Online
Article
Text
id pubmed-8851028
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-88510282022-02-28 An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy Filippini, Tommaso Zagnoli, Federico Bosi, Matteo Giannone, Maria Edvige Marchesi, Cristina Vinceti, Marco Acta Biomed Original Investigations/Commentaries BACKGROUND AND AIM: The exact COVID-19 severity is still not well defined and it is hotly debated due to a few methodological issues such as the uncertainties about the spread of the SARS-CoV-2 infection. METHODS: We investigated COVID-19 case-fatality rate and infection-fatality rate in 2020 in Italy, a country severely affected by the pandemic, basing our assessment on publicly available data, and calculating such measures during the first and second waves. RESULTS: We found that province-specific crude case-fatality rate in the first wave (February-July 2020) had a median value of 12.0%. Data about infection-fatality rate was more difficult to compute, due to large underestimation of SARS-CoV-2 infection during the first wave when asymptomatic individuals were very rarely tested. However, when using reference population-based seroprevalence data for anti-SARS-CoV-2 antibodies collected in May-July 2020, we computed an infection-fatality rate of 2.2%. During the second wave (Sep-Dec 2020), when SARS-CoV-2 testing was greatly increased and extended to many asymptomatic individuals, we could only compute a ‘hybrid’ case/infection-fatality rate with a value of 2.2%, similar to the infection-fatality rate of the first wave. CONCLUSIONS: Overall, this study allowed to assess the COVID-19 case- and infection-fatality rates in Italy before of variant spread and vaccine availability, confirming their high values compared with other airborne infections like influenza. Our findings for Italy were similar to those characterizing other Western European countries. Mattioli 1885 2021 2021-10-01 /pmc/articles/PMC8851028/ /pubmed/34739462 http://dx.doi.org/10.23750/abm.v92iS6.12241 Text en Copyright: © 2021 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Original Investigations/Commentaries
Filippini, Tommaso
Zagnoli, Federico
Bosi, Matteo
Giannone, Maria Edvige
Marchesi, Cristina
Vinceti, Marco
An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy
title An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy
title_full An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy
title_fullStr An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy
title_full_unstemmed An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy
title_short An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy
title_sort assessment of case-fatality and infection-fatality rates of first and second covid-19 waves in italy
topic Original Investigations/Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851028/
https://www.ncbi.nlm.nih.gov/pubmed/34739462
http://dx.doi.org/10.23750/abm.v92iS6.12241
work_keys_str_mv AT filippinitommaso anassessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT zagnolifederico anassessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT bosimatteo anassessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT giannonemariaedvige anassessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT marchesicristina anassessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT vincetimarco anassessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT filippinitommaso assessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT zagnolifederico assessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT bosimatteo assessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT giannonemariaedvige assessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT marchesicristina assessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly
AT vincetimarco assessmentofcasefatalityandinfectionfatalityratesoffirstandsecondcovid19wavesinitaly